<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00771823</url>
  </required_header>
  <id_info>
    <org_study_id>SSAT025</org_study_id>
    <secondary_id>2007-004477-25</secondary_id>
    <nct_id>NCT00771823</nct_id>
  </id_info>
  <brief_title>Maraviroc 300 mg Twice Daily in HIV Negative Male Volunteers</brief_title>
  <official_title>A Placebo Controlled Study of the Impact on Insulin Sensitivity and Lipid Profile of Maraviroc 300 mg Twice Daily in HIV Negative Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St Stephens Aids Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St Stephens Aids Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A placebo controlled study of the impact on insulin sensitivity and lipid profile of
      maraviroc 300 mg twice daily in HIV negative male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in insulin sensitivity by euglycaemic clamp method</measure>
    <time_frame>two weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in serum levels of fasting cholesterol, triglycerides Changes in serum biomarkers of vascular inflammation and in CD36 PMBC and other related markers gene expression</measure>
    <time_frame>two weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Maraviroc 300 mg twice daily for the first 14 days of the study.
Placebo twice daily for the last 14 days of the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maraviroc</intervention_name>
    <description>Maraviroc 300 mg twice daily for the first 14 days of the study. Placebo twice daily for the last 14 days of the study</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maraviroc</intervention_name>
    <description>Placebo twice daily for the first 14 days of the study.
Maraviroc 300 mg twice daily for the last 14 days of the study.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must have documented negative HIV serology by ELISA and P24 antigen

          -  Subjects must be clinically well males aged between 18 to 60 years.

          -  Fasting blood glucose, total cholesterol and triglycerides within normal limits

          -  Hepatic transaminases (AST and ALT) ≤ 3 × upper limit of normal (ULN)

          -  Adequate hematologic function (absolute neutrophil count ≥ 1,000/mm3; platelets ≥
             50,000/mm3; hemoglobin ≥ 8.0 g/dL)

          -  Serum amylase ≤ 1.5 × ULN

          -  Sexually active males must use condoms during the course of the study

          -  Life expectancy ≥ 1 year

          -  Willing and able to provide informed consent

        Exclusion Criteria:

          -  Subjects with a waist hip ratio &gt; 0.97 or BMI &gt; 28 kg/m2 will be excluded

          -  Acute or chronic hepatitis B infection (determined by positive hepatitis B surface
             antigen result at the screening visit)

          -  Acute or chronic hepatitis C infection (determined by positive hepatitis C antibody
             result at the screening visit)

          -  Other metabolic syndrome or disease process in the opinion of the investigator likely
             to cause marked disturbance in glucose and lipid homeostasis including hypertension.

          -  Receiving on-going therapy with any of the following:

               -  Metabolically active medications

               -  Any lipid-lowering medication

               -  Hormonal agents (oestrogens or androgens)

               -  Glucocorticoids

               -  Beta-blockers

               -  Thiazide diuretics

               -  Thyroid preparations

               -  Psychotropic agents

               -  Anabolic steroids

               -  Megestrol acetate
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Graeme Moyle</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Stephen's AIDS Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chelsea and Westminster Hospital</name>
      <address>
        <city>London</city>
        <zip>SW10 9TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2008</study_first_submitted>
  <study_first_submitted_qc>October 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2008</study_first_posted>
  <last_update_submitted>August 13, 2010</last_update_submitted>
  <last_update_submitted_qc>August 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr Graeme Moyle</name_title>
    <organization>St Stephen's AIDS Trust</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Maraviroc</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

